文献速递骨软组织肉瘤与黑色素瘤

CheckMate 238中切除黑色素瘤辅助检查点抑制剂治疗后复发后系统治疗的结局

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.
PubMed 文献 · J Clin Oncol · 2024-08-05

在III期CheckMate 238中,纳武利尤单抗辅助治疗较伊匹木单抗显著改善切除IIIB-C/IV期黑色素瘤的无复发生存,总生存无显著差异。本研究分析复发后接受系统治疗的无进展生存和总生存,发现复发>12个月者复发后生存更长,纳武利尤单抗治疗后早期复发者接受伊匹木单抗方案或靶向治疗生存优于抗PD-1单药。

要点

  • 纳武利尤单抗组复发198例(44%),其中早期122例、晚期76例;伊匹木单抗组复发232例(51%),早期160例、晚期72例。
  • 纳武利尤单抗组早期复发者后续系统治疗中位PFS 4.7个月,晚期复发者12.4个月。
  • 纳武利尤单抗组早期复发者后续系统治疗中位OS 19.8个月,晚期复发者42.8个月。

核心结论

  • 复发时间>12个月的患者复发后生存更长。
  • 纳武利尤单抗治疗后早期复发者从后续系统治疗中获益,但接受伊匹木单抗为基础方案或靶向治疗的生存优于抗PD-1单药。

研究设计与样本

  • III期CheckMate 238研究,纳入15岁及以上切除IIIB-C/IV期黑色素瘤患者,按分期和肿瘤PD-L1状态分层随机分配。
  • 纳武利尤单抗组453例接受纳武利尤单抗3 mg/kg每2周;伊匹木单抗组453例接受伊匹木单抗10 mg/kg每3周共4次,之后每12周共1年,直至疾病复发、不可接受毒性或撤回知情同意。
  • 对两组复发患者,从后续系统治疗(SST)启动时评估PFS和OS,按复发时间(自初始治疗起≤12个月为早期 vs >12个月为晚期)分析。

主要发现

  • 纳武利尤单抗组453例中复发198例(44%),其中早期复发122例、晚期复发76例;伊匹木单抗组453例中复发232例(51%),早期160例、晚期72例。
  • 纳武利尤单抗治疗患者早期复发 vs 晚期复发:后续系统治疗中位PFS 4.7个月 vs 12.4个月(24个月率16% vs 31%);中位OS 19.8个月 vs 42.8个月(24个月率37% vs 73%)。
  • 纳武利尤单抗治疗晚期复发者较早期复发者更可能从抗PD-1单药治疗中获益。
  • 纳武利尤单抗治疗早期或晚期复发者均从伊匹木单抗为基础治疗或靶向治疗中获益,两者OS相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In phase III CheckMate 238, adjuvant nivolumab significantly improved recurrence-free survival compared with ipilimumab in patients with resected stage IIIB-C/IV melanoma without a significant difference in overall survival (OS). Here, we investigate progression-free survival (PFS) and OS after postrecurrence systemic therapy. PATIENTS AND METHODS: Patients 15 years or older with resected stage IIIB-C/IV melanoma were stratified by stage and tumor PD-L1 status and randomly assigned to receive nivolumab 3 mg/kg every 2 weeks, or ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks for 1 year or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Patients with recurrence in each group were assessed for PFS and OS from subsequent systemic therapy (SST) initiation per recurrence timing (≤12 months [early] v >12 months [late] from initial therapy). RESULTS: Recurrences occurred in 198 (44%) of 453 nivolumab-treated patients (122 early, 76 late) and 232 (51%) of 453 ipilimumab-treated patients (160 early, 72 late). Median PFS on next-line systemic therapy for nivolumab-treated patients recurring early versus late was 4.7 versus 12.4 months (24-month rates, 16% v 31%); median OS was 19.8 versus 42.8 months (24-month rates: 37% v 73%). In response to subsequent therapy, patients on nivolumab with late versus early recurrence were more likely to benefit from anti-PD-1 monotherapy. Nivolumab-treated patients with either an early or late recurrence benefitted from an ipilimumab-based therapy or targeted therapy, each with similar OS. CONCLUSION: Postrecurrence survival was longer for patients who recurred >12 months. Patients on nivolumab who recurred early benefitted from SST but had better survival with ipilimumab-based regimens or targeted therapy compared with anti-PD-1 monotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Weber J, Del Vecchio M, Mandalá M, et al. Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238. J Clin Oncol. 2024. PMID: 39102624. doi:10.1200/JCO.23.01448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。